Table 4 PheWAS findings of all eMERGE participants at FDR < 0.05, N = 97,991 for two best variants in this study (rs6567160, rs2229616 (V103I)).

Description	SNP	Beta	SE	P	n_cases	n_controls	FDR
Obesity	rs6567160_C	0.098	0.014	8.36E−13	19253	66096	TRUE
Overweight	rs6567160_C	0.093	0.013	9.63E−13	22435	66096	TRUE
Morbid obesity	rs6567160_C	0.142	0.021	9.74E−12	6902	66096	TRUE
Type 2 diabetes	rs2229616_T	−0.291	0.051	8.48E−09	17950	67153	TRUE
Diabetes mellitus	rs2229616_T	−0.274	0.050	3.50E−08	18502	67153	TRUE
Overweight	rs2229616_T	−0.218	0.044	6.49E−07	22435	66096	TRUE
Hypertensive chronic kidney disease	rs2229616_T	−0.432	0.088	8.37E−07	6866	46505	TRUE
Morbid obesity	rs2229616_T	−0.377	0.078	1.39E−06	6902	66096	TRUE
Type 2 diabetic nephropathy	rs2229616_T	−0.573	0.120	1.71E−06	3322	67153	TRUE
Obesity	rs2229616_T	−0.221	0.047	2.08E−06	19253	66096	TRUE
Dysmetabolic syndrome X	rs6567160_C	0.221	0.048	4.00E−06	1118	89648	TRUE
Other anemias	rs2229616_T	−0.191	0.046	3.89E−05	21199	61540	TRUE
Chronic renal failure	rs2229616_T	−0.248	0.061	4.67E−05	11298	69924	TRUE
Type 2 diabetic neuropathy	rs2229616_T	−0.408	0.104	8.49E−05	3775	67153	TRUE
Nephritis; nephrosis; renal sclerosis	rs2229616_T	−0.434	0.111	8.84E−05	3685	69924	TRUE
Iron deficiency anemias NOS	rs2229616_T	−0.281	0.072	9.23E−05	7765	61540	TRUE
Hyperglyceridemia	rs6567160_C	0.140	0.036	9.80E−05	2293	47879	TRUE
Malignant neoplasm of small intestine	rs6567160_C	0.466	0.120	1.06E−04	159	86863	TRUE
Hypertension	rs2229616_T	−0.172	0.045	1.15E−04	44417	46505	TRUE
Chronic venous insufficiency	rs6567160_C	0.129	0.034	1.19E−04	2588	64412	TRUE
Bariatric surgery	rs2229616_T	−0.682	0.178	1.28E−04	1809	94483	TRUE

Quick links

Search